<DOC>
	<DOCNO>NCT00157105</DOCNO>
	<brief_summary>The purpose study evaluate whether rAHF-PFM safe effective treatment hemophilia A patient undergoing surgery .</brief_summary>
	<brief_title>Safety Efficacy Study Recombinant Protein-Free Factor VIII ( rAHF-PFM ) Hemophilia A Patients Undergoing Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Age &gt; = 5 year The subject severe moderately severe hemophilia A defined baseline factor VIII level &lt; = 2 % normal document screen historically ( e.g. , hemophilia diagnosis ) Subjects may enroll regardless serologic status human immunodeficiency virus ( HIV1 ) hepatitis C virus ( HCV ) The subject require surgical , dental invasive procedureeither elective emergency The subject history least 150 exposure day factor VIII product ( estimate study site investigator ) prior study entry The subject life expectancy least 28 day day surgery The subject inform nature study , agree provision , sign date informed consent form approve appropriate IRB/IEC Baxter BioScience The subject detectable inhibitor factor VIII local hemostasis laboratory investigative site time enrollment The subject history inhibitor factor VIII &gt; 1.0 BU . Note : If subject history inhibitor titer &gt; 1.0 BU time prior enrollment demonstrate expected clinical response conventional dos factor VIII therapy , subject may enroll The subject know hypersensitivity Recombinate The subject currently participate another investigational drug study , participate clinical trial involve investigational drug within 30 day study entry The subject clinical and/or laboratory evidence abnormal hemostasis cause hemophilia A ( e.g. , latestage chronic liver disease , immune thrombocytopenic purpura , disseminate intravascular coagulation ) The subject identify investigator unable unwilling cooperate study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>